Announcement of Shandong Buchang Pharmaceutical Co., Ltd. on the first repurchase of shares through centralized bidding transactions
Securities code: 603858 Securities abbreviation: Buchang Pharmaceutical Announcement number: 2026-083
Shandong Buchang Pharmaceutical Co., Ltd.
Announcement on the first repurchase of shares through centralized bidding transactions
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents.
Important content reminder:
The first disclosure date of the repurchase plan is 2026/5/26
The implementation period of the repurchase plan is 12 months after it is reviewed and approved by the board of directors
The estimated repurchase amount is 75 million yuan to 150 million yuan
□Reduce registered capital
√Used for employee stock ownership plans or equity incentives
Repurchase purpose
√ Used to convert company convertible bonds
□To protect the company’s value and shareholders’ rights and interests
The cumulative number of shares repurchased is 1,974,600 shares
The cumulative number of shares repurchased accounts for 0.19% of the total share capital.
The cumulative repurchased amount is RMB 29.9813 million
The actual repurchase price range is 14.98 yuan/share~15.33 yuan/share
1. Basic information on share repurchase
Shandong Buchang Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") held the 49th meeting of the fifth board of directors on May 25, 2026, and reviewed and approved the "Proposal on the Plan for Repurchasing Shares through Centralized Bidding Transactions", and agreed that the company would use its own funds and special loans from financial institutions to repurchase public shares to repurchase public shares through centralized bidding transactions. Under the condition that the upper limit of the share repurchase price is 21.00 yuan per share, and based on the lower limit of the proposed share repurchase amount of 75 million yuan, the number of repurchasable shares is estimated to be approximately 3,571,429 yuan. The estimated number of repurchasable shares is approximately 7,142,857 shares, based on the upper limit of the proposed share repurchase amount of 150 million yuan. The repurchase period is no more than 12 months from the date the board of directors considers and approves the share repurchase proposal. months. For specific details, please refer to the "Announcement on the Plan to Repurchase Shares through Centralized Bidding Transactions and Obtaining a Commitment Letter for Repurchasing Special Loans from Financial Institutions" (Announcement No.: 2026-072) and the "Repurchase Report on the Repurchase of Shares through Centralized Bidding Transactions" (Announcement No.: 2026-080) disclosed by the company on the Shanghai Stock Exchange website (www.sse.com.cn) on May 26, 2026 and June 2, 2026.
2. Progress of share repurchase
In accordance with the "Share Repurchase Rules of Listed Companies", "Shanghai Stock Exchange Self-Discipline Supervision Guidelines for Listed Companies No. 7 - Repurchase of Shares" and other relevant regulations, the company's first share repurchase is now announced as follows:
On June 2, 2026, the company repurchased 1,974,600 company shares for the first time through centralized bidding transactions. The repurchased shares accounted for 0.19% of the company's total share capital. The highest purchase price was 15.33 yuan/share and the lowest price was 14.98 yuan/share. The cumulative total amount paid was 29,981,338.40 yuan (excluding transaction fees). There is a tail difference in the proportion of repurchased shares, which is caused by rounding.
This repurchase complies with relevant laws and regulations and the requirements of the company's share repurchase plan.
3. Other matters
The company will strictly abide by the "Share Repurchase Rules for Listed Companies", "Shanghai Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 7 - Repurchase of Shares" and other relevant regulations, make repurchase decisions based on market conditions during the repurchase period and implement them. At the same time, it will perform information disclosure obligations in a timely manner based on the progress of the share repurchase matter. Investors are advised to pay attention to investment risks.
Announcement is hereby made.
Board of Directors of Shandong Buchang Pharmaceutical Co., Ltd.
June 3, 2026